(CMMB) Chemomab Therapeutics Ltd. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(CMMB) Chemomab Therapeutics Ltd. Complete Analysis Pack
Unlock Strategic Clarity
This Chemomab Therapeutics Ltd. BCG Matrix helps you understand how the company’s products or business units may fit into the Stars, Cash Cows, Question Marks, and Dogs framework for strategy and portfolio review. What you see on this page is a real preview of the actual analysis, not just marketing text, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
0 approved products
Chemomab Therapeutics Ltd. had 0 approved products through end-2025, so it had no commercial drug to qualify as a Star. The company remained a clinical-stage biotech, with value driven by pipeline execution and trial readouts rather than sales. In BCG terms, this points to question-mark economics, not a high-share, cash-generating brand.
0 product sales
Chemomab Therapeutics Ltd. reported 0 product sales, because no drug had been commercialized in fiscal 2025. With no revenue stream, there was no sales momentum to show in a growing market. A Star needs both high growth and market leadership, and Chemomab did not have either.
0 recurring royalties
Chemomab Therapeutics Ltd. had 0 recurring royalties because it had no approved asset generating an established royalty stream. That meant no Star-like cash engine to scale revenue; as of its latest public filings, the Company remained development-led, not commercial-led. In 2025, Chemomab reported no product sales and continued to fund R&D from cash and financing.
1 lead asset only
Chemomab Therapeutics Ltd. was highly concentrated around CM-101, its only lead asset, but that still did not make it a Star. CM-101 was in clinical development, so it had no commercial share or market leadership yet. In its latest reported filings, Chemomab still had no product revenue, which fits a pipeline-stage story, not a market winner.
- One asset drives the whole equity story
- Development risk remains high
- No sales means no Star status yet
0 market-leading brand
Chemomab Therapeutics Ltd. had no market-leading brand in PSC, SSc, or any other indication, and it still had no approved product sales, so the business was not in Star territory. The pipeline was still proving clinical and regulatory value, with lead asset nebokitug (CM-101) remaining in development rather than commercialization.
That means Chemomab Therapeutics Ltd. had "0" first-mover commercial dominance and "0" established revenue engine from a flagship product, which is why this fits a pre-Star profile. In FY2025/2026 terms, the key test is still approval and uptake, not brand leadership.
- No approved products
- No PSC brand dominance
- No SSc brand dominance
- Pipeline still needs validation
Chemomab FY2025: No Stars, No Sales, Pure Clinical-Stage Risk
Chemomab Therapeutics Ltd. had no Stars in FY2025, because it had 0 approved products, 0 product sales, and no commercial market share. The Company stayed a clinical-stage biotech, led by nebokitug (CM-101), with value tied to trial data, not revenue. That is pre-Star, not Star, economics.
| FY2025 metric | Value |
|---|---|
| Approved products | 0 |
| Product sales | 0 |
| Star status | No |
What is included in the product
Detailed Word Document
Chemomab’s BCG Matrix likely centers on one high-potential pipeline Question Mark, with no Cash Cows and elevated binary risk.
Editable Excel File
Quick BCG snapshot of Chemomab Therapeutics Ltd. to spot cash drains and growth bets fast.
Reference Sources
Shows the source trail behind Chemomab Therapeutics Ltd. claims, helping investors verify assumptions fast and make decisions with more confidence.
Cash Cows
0 mature products
Chemomab Therapeutics Ltd. had 0 mature products by end 2025, so it had no cash cow in the BCG sense. Cash cows need a low-growth, high-share franchise that throws off steady cash, but Chemomab still reported no approved product and remained in development, with R&D spending at about $20.0 million in 2025. So the business had not entered a harvest phase.
0 steady product revenue
Chemomab Therapeutics Ltd. had $0 recurring product revenue, so it had no cash cow to fund the business. In FY2025, R&D still drove cash burn, which kept operating cash outflows above zero and left the company dependent on outside financing. That is the opposite of a BCG cash cow: it consumed cash instead of generating surplus cash.
0 high-margin commercial franchise
Chemomab Therapeutics Ltd. had no marketed drug in 2025, so it had no high-margin commercial cash cow. Mature biotech cash cows usually come from approved therapies with steady sales and gross margins often above 80%, but Chemomab was still pre-commercial, with no product revenue reported in its latest filings.
0 self-funding asset
Chemomab Therapeutics Ltd had no approved product generating self-funding cash, so its trial work and corporate overhead still depended on external capital. That is the opposite of a Cash Cow profile in a BCG Matrix. In 2025, the Company remained a development-stage biotech, with R&D spending and G&A outpacing any operating inflow.
- No product revenue
- R&D needed outside funding
- Overhead was not self-funded
0 dividend-supporting business unit
Chemomab Therapeutics Ltd. had no dividend-supporting business unit, because it had no commercial product base in 2025. With 0 product revenue, it could not use cash cows to fund dividends, debt service, or heavy reinvestment, so Chemomab was not in that position.
- No commercial cash cow in 2025
- 0 product revenue base
- No dividend capacity from operations
- Still dependent on external funding
Chemomab Had No Cash Cow in FY2025: $0 Revenue, $20M R&D Burn
Chemomab Therapeutics Ltd. had no Cash Cow in FY2025. It reported $0 product revenue, no approved drug, and about $20.0 million in R&D spend, so operations still consumed cash instead of funding growth or dividends.
| Metric | FY2025 |
|---|---|
| Product revenue | $0 |
| R&D expense | $20.0 million |
| Approved products | 0 |
| Cash Cow status | No |
Preview Before You Purchase
Chemomab Therapeutics Ltd. Reference Sources
The Chemomab Therapeutics Ltd. BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. No demo content or placeholders—just the full, professionally formatted report. Once purchased, it’s ready for immediate download, editing, or presentation. What you see here is what you get.
Dogs
0 commercial products
As of FY2025, Chemomab Therapeutics Ltd. had 0 commercial products, so there was no clear low-growth, low-share Dog asset to point to. The company’s value stayed in development-stage programs, not in marketed sales. In BCG terms, the Dog bucket was essentially empty because the portfolio had no mature product revenue base.
0 obsolete brand base
Chemomab Therapeutics had no legacy branded drug portfolio to harvest or wind down in 2025, and it remained a clinical-stage company with 0 product revenue. The 2021 rebrand from Anchiano Therapeutics changed the name, not the business model. No mature product line was carried as a weak commercial asset; the focus stayed on investigational assets such as nebokitug (CM-101).
0 stranded revenue stream
Chemomab Therapeutics Ltd. had $0 disclosed product revenue in FY2025, so it did not have a mature sales line that could slide into a Dog profile. The issue was absence of revenue, not decay of revenue. With no sales base, there was no underperforming product to classify as stranded income.
0 divestable product unit
Chemomab Therapeutics Ltd. had no divestable product unit to classify as a Dog in its BCG Matrix. The Company was built around one clinical asset, so there was no separate low-share, low-growth business to sell or exit. Its 2025 reporting also showed no product revenue, which fits a single-asset biotech model.
- No separate unit reported for sale
- One lead clinical asset drove the model
- No product revenue in 2025
High cash burn, low cash inflow
Chemomab Therapeutics Ltd.'s high cash burn reflects a clinical-stage biopharma model: capital goes into R&D, trials, and regulation long before sales start. That pressure is real, but it points to company stage, not a true BCG "Dog" asset, because the portfolio still lacks a mature, revenue-generating product.
- Spends before revenue
- Burn tracks trial costs
- No mature cash engine yet
- Stage risk, not product failure
Chemomab Has No “Dog” Asset in FY2025
In FY2025, Chemomab Therapeutics Ltd. had no commercial products and $0 product revenue, so there was no true Dog asset in its BCG mix. The portfolio was still centered on one clinical-stage lead asset, nebokitug (CM-101), not a weak legacy product. So the Dog bucket stayed empty: no mature sales line, no divestable underperformer.
| Metric | FY2025 |
|---|---|
| Product revenue | $0 |
| Commercial products | 0 |
| Lead asset | nebokitug (CM-101) |
| Dog classification | None |
Question Marks
CM-101 in primary sclerosing cholangitis
CM-101 was Chemomab Therapeutics Ltd.’s lead investigational antibody for primary sclerosing cholangitis, a rare inflammatory-fibrotic liver disease affecting about 1 to 16 people per 100,000 in Western populations. With no approved curative therapy and high unmet need, the asset had clear upside, but it had no commercial share yet. That is why it fit the Question Mark quadrant: high potential, low current traction.
CM-101 in systemic sclerosis
CM-101 in systemic sclerosis stayed a Question Mark: a high-uncertainty, high-upside bet where clinical proof was the key gate to value creation. Systemic sclerosis affects about 75,000 to 100,000 people in the U.S., so even modest efficacy could matter, but the asset still needed clear data to justify value. Until approval, Chemomab Therapeutics Ltd. had to treat this program as optional upside, not core value.
Anti-CCL24 monoclonal antibody platform
CM-101 targets soluble CCL24, a fibrosis-and-inflammation pathway, and gave Chemomab a clear scientific edge. But it was still a clinical-stage asset with no commercial sales or market share, so the platform stayed in classic Question Mark territory. The upside was real, but so was the proof risk, since the platform had not yet converted mechanism into revenue.
Single-asset pipeline concentration
Chemomab Therapeutics Ltd. is still heavily tied to one lead asset, nebokitug (CM-101), so its pipeline has little cushion if results miss. That makes the stock a clear Question Mark in BCG terms: high upside if clinical data and financing stay on track, but high failure risk if the lead program slips. The company’s value is still driven by this single program, not a broad commercial base.
- One lead asset drives most value.
- Positive data could re-rate sharply.
- Any setback raises survival risk.
Rare-disease expansion optionality
Chemomab Therapeutics Ltd.’s fibrosis core left room to test rare-disease expansion, but only after clinical and regulatory proof. These uses were still Question Marks because they had no established revenue and depended on success in lead programs. In BCG terms, they were upside bets, not core businesses.
- Fibrosis focus created spare indication runway
- Expansion needed trial and FDA/EMA wins
- Rare-disease uses remained unproven Question Marks
Chemomab’s High-Risk, High-Need Pipeline Drives its Question Mark Status
Chemomab Therapeutics Ltd.’s Question Marks were nebokitug (CM-101) and new fibrosis indications: high unmet need, no sales, and binary clinical risk. As a 2025 micro-cap biotech, it had no commercial cushion, so value still depended on trial data and funding, not market share.
| Item | Latest data |
|---|---|
| Nebokitug | Lead asset, no sales |
| PSC prevalence | 1 to 16 per 100,000 |
| Systemic sclerosis | 75,000 to 100,000 U.S. cases |
| BCG label | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.